EUS Guided HVA and PVA for Circulating Tumor DNA in Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorChinese University of Hong Kong
About this trial
The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics. The investigators plan to perform EUS-guided portal vein and hepatic vein aspiration in GI cancers patients. The aim of the current study is thus to examine the concentration of ctDNA in portal vein (EUS-guided PVA), hepatic vein (EUS-guided HVA) and peripheral blood to understand the first pass effect of the liver with gastrointestinal (GI) cancers, and the possibility of using ctDNA as a marker for preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for recurrence.
Eligibility criteria
Qualifiers
Age >= 18 years old
Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer
Surgery
Neoadjuvant chemotherapy
Disqualifiers
Synchronous cancer of other sites
Cardia, high lesser curve tumors, oesophagogastric junction tumors
Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein
Patients with coagulopathy (international normalized ratio >1.3, partial thromboplastin time greater than twice that of control), platelet count <50,000x103/uL
Trial design
Treatments tested in this trial
- EUS-guided portal vein and hepatic vein aspiration
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov